111 related articles for article (PubMed ID: 4601671)
1. Toxicity study of BCNU (NSC-409962) given orally.
Lessner HE; Vogler WR
Cancer Chemother Rep; 1974; 58(3):407-11. PubMed ID: 4601671
[No Abstract] [Full Text] [Related]
2. BCNU (NSC-409962) in the treatment of advanced Hodgkin's disease, lymphosarcoma, and reticulum cell sarcoma.
Rege VB; Owens AH
Cancer Chemother Rep; 1974; 58(3):383-92. PubMed ID: 4601668
[No Abstract] [Full Text] [Related]
3. DTIC (NSC-45388) studies in the southwest oncology group.
Costanzi JJ
Cancer Treat Rep; 1976 Feb; 60(2):189-92. PubMed ID: 769972
[TBL] [Abstract][Full Text] [Related]
4. Clinical evaluation of 1,3-bis(2-chloroethyl)-nitrosourea (BCNU; NSC-409962) with fluoxymesterone (NSC-12165) in the treatment of solid tumors.
Reyes ES; Talley RW; O'Bryan RM; Gastesi RA
Cancer Chemother Rep; 1973 Apr; 57(2):225-30. PubMed ID: 4582564
[No Abstract] [Full Text] [Related]
5. Development of four-drug BCNU combination chemotherapy regimens.
Durant JR; Lessner HE
Cancer; 1973 Aug; 32(2):277-85. PubMed ID: 4722913
[No Abstract] [Full Text] [Related]
6. Therapy of advanced gastrointestinal cancer with the nitrosoureas.
Moertel CG
Cancer Chemother Rep 3; 1973 May; 4(3):27-34. PubMed ID: 4748872
[No Abstract] [Full Text] [Related]
7. Phase II evaluation of BCNU and 5-FU in gastrointestinal carcinomas.
Tormey DC; Gailani S; Leone L
Oncology; 1974; 29(3):244-8. PubMed ID: 4415043
[No Abstract] [Full Text] [Related]
8. Clinical toxicity of combined modality treatment with nitrosourea derivatives for central nervous system tumors.
Robustelli della Cuna G; Paoletti P; Bernardo G; Knerich R; Butti G; Cuzzoni Q
Neurosurgery; 1982 Sep; 11(3):408-11. PubMed ID: 6290930
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of hexamethylmelamine (NSC 13875).
Wilson WL; Schroeder JM; Bisel HF; Mrazek R; Hummel RP
Cancer; 1969 Jan; 23(1):132-6. PubMed ID: 5812585
[No Abstract] [Full Text] [Related]
10. BCNU (NSC-409962) in the treatment of advanced Hodgkin's disease: its role in remission induction and maintenance.
Anderson T; DeVita T; Young RC
Cancer Treat Rep; 1976 Jun; 60(6):761-7. PubMed ID: 782698
[TBL] [Abstract][Full Text] [Related]
11. [On the therapy of lymphogranuloma. CCNU (1(2-chlorethyl)-3-cyclohexyl-1-nitrosourea) and BCNU (1,3-bis(2-chlorethyl)-1-nitrosourea) as well as BCNU combinations in Hodgkin's lymphogranuloma, stage 3 and 4].
Brunner KW; Maurice P; Sonntag RW
Schweiz Med Wochenschr; 1972 Oct; 102(43):1546-51. PubMed ID: 4647016
[No Abstract] [Full Text] [Related]
12. [Preventive and therapeutic measures in cytostatic-associated toxicity].
Cerny T; Buser K; Kiser J; Joss RA
Schweiz Med Wochenschr; 1990 Sep; 120(37):1353-62. PubMed ID: 2218458
[TBL] [Abstract][Full Text] [Related]
13. The chemotherapy of brain tumors. Clinical experience with carmustine (BCNU) and vincristine.
Fewer D; Wilson CB; Boldrey EB; Enot KJ; Powell MR
JAMA; 1972 Oct; 222(5):549-52. PubMed ID: 4343318
[No Abstract] [Full Text] [Related]
14. Treatment of Hodgkin's disease and other cancers with 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; NSC-409962).
Marsh JC; DeConti RC; Hubbard SP
Cancer Chemother Rep; 1971 Dec; 55(5):599-606. PubMed ID: 4334161
[No Abstract] [Full Text] [Related]
15. The efficacy of animal studies in predicting clinical toxicity of cancer chemotherapeutic drugs.
Schein P; Anderson T
Int J Clin Pharmacol; 1973 Nov; 8(3):228-38. PubMed ID: 4203921
[No Abstract] [Full Text] [Related]
16. Response of advanced breast cancer to two dosage regiments of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; NSC-409962).
Bonnet JD; Brownlee RW; Vaitkevicius VK; Talley RW
Cancer Chemother Rep; 1973 Apr; 57(2):231-4. PubMed ID: 4742501
[No Abstract] [Full Text] [Related]
17. Evaluation of cyclophosphamide (NSC-26271) and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; NSC-409962) in the treatment of patients with inoperable or disseminated lung cancer.
Ahmann DL; Carr DT; Coles DT; Hahn RG
Cancer Chemother Rep; 1972 Jun; 56(3):401-3. PubMed ID: 19051501
[TBL] [Abstract][Full Text] [Related]
18. Toxicity of nonsteroidal anti-inflammatory drugs.
Med Lett Drugs Ther; 1983 Feb; 25(628):15-6. PubMed ID: 6823224
[No Abstract] [Full Text] [Related]
19. Aminoglutethimide-induced hematologic toxicity: worldwide experience.
Messeih AA; Lipton A; Santen RJ; Harvey HA; Boucher AE; Murray R; Ragaz J; Buzdar AU; Nagel GA; Henderson IC
Cancer Treat Rep; 1985 Sep; 69(9):1003-4. PubMed ID: 4028032
[TBL] [Abstract][Full Text] [Related]
20. Primary treatment of disseminated Hodgkin's disease with BCNU alone and in combination with vincristine, procarbazine, and prednisone.
Harrison DT; Neiman PE
Cancer Treat Rep; 1977 Aug; 61(5):789-95. PubMed ID: 329978
[No Abstract] [Full Text] [Related]
[Next] [New Search]
